Articles tagged with Liver
CellCept shows benefits for liver transplant patients, similar to those seen in kidney transplant recipients, with reduced risk of acute rejection and improved kidney function. The treatment also promotes safe steroid-free regimens and reduces liver fibrosis.
A recent study found a significant percentage of patients who received a liver transplant due to alcoholic liver disease also used tobacco post-transplant. The majority of smokers resumed their habit quickly and showed increased consumption over time, highlighting the need for more stringent monitoring and intervention.
A seven-year review of liver transplant recipients who received HBV positive and HCV positive organs found patient and graft survival rates comparable to those receiving livers from negative donors. The use of these organs increases the number available for transplantation while maintaining long-term results.
Researchers have made a groundbreaking discovery by directly observing the liver invasion of malarial parasites using intravital microscopy. The study reveals a critical stage in the parasite's life cycle, where sporozoites traverse Kupffer cells to wreak havoc on liver tissue.
A steroid-free regimen with CellCept was found to be comparable to standard therapy in liver transplantation, without increasing the risk of hepatitis C recurrence. The study involved 312 adult patients and showed that the CellCept-based regimen demonstrated comparable efficacy and safety profiles.
Researchers have found promising results from an early clinical trial of a novel treatment for uveal melanoma that has spread to the liver. The two-pronged treatment cuts off oxygen supply to tumors and stimulates the immune system, leading to tumor shrinkage and prolonged survival in patients.
Researchers found grapefruit seed extract accelerates ulcer healing by reducing gastric acid secretion and promoting blood flow at the ulcer site. The study suggests that grapefruit can be a beneficial addition to the diet for those with ulcers.
Children under five are most likely to die waiting for a liver transplant due to organ shortage. Living donor liver transplantation offers better graft and patient survival rates for pediatric patients.
Researchers found that ablation therapy extended median survival to 33 months compared to 20 months for chemotherapy-only treatment. The study also showed improved disease recurrence rates and overall 3-year survival rate of 51%.
Researchers found that increased LXR expression in the liver improves cholesterol and triglyceride levels on high-fat diets, but loses effect with experimental drugs. The study suggests that targeting natural ligands may be more effective in treating metabolic diseases.
A new study published in Cell Metabolism found that normal metabolism requires so-called "new" fat to maintain glucose, lipid, and cholesterol homeostasis. The researchers discovered that old fat stores alone failed to set critical metabolic pathways in motion, leading to a marked decline in gene activity.
A new study reveals that mice with an excess of liver X receptor (LXRa) are protected from high-fat diet-induced cholesterol and blood vessel plaques. The findings suggest that natural variation in LXRa levels can influence susceptibility to heart disease, depending on diet.
Genetically engineered mice with a missing enzyme in their livers developed fatty liver disease when placed on a zero-fat diet. The study found that consuming new fat, which is produced in the liver or consumed in food, helps regulate fat burning and prevents liver damage.
Researchers found that liver cells express CB1 receptors, which activate a signaling pathway increasing fatty acid synthesis. This activation is similar to brain and may be a target for metabolic regulation and appetite control.
New research reveals that accumulated liver lipids originate from serum fatty acids, newly produced fatty acids within the liver, and dietary fatty acids. The study also highlights the potential role of endocannabinoids in regulating liver metabolism and appetite control. Additionally, a companion paper explores the relationship betwee...
A recent study led by Elizabeth Parks from the University of Minnesota has made a groundbreaking discovery about the origin of fatty liver disease. The research found that excess dietary fat can lead to liver toxicity, causing it to malfunction in its role as the body's central storage and distribution center for fat.
Accumulated liver lipids come from serum fatty acids, newly made fatty acids within the liver, and dietary fatty acids. Insulin-sensitizing agents may help reduce oxidative stress and treat NAFLD.
A study of Southern Italian residents found that over 12% had abnormal liver values, with a significant correlation between age, gender, and excessive alcohol consumption. Nonalcoholic fatty liver disease emerged as an important cause of altered liver tests in the region.
Research finds that high cyclosporine levels are associated with increased risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation. The study suggests tailoring immunosuppressive schedules to individual patients based on their tumor biology, and recommends minimizing exposure to cyclosporine to prevent recurrence.
Researchers found that nitrite therapy reduces cell death and preserves organ function in mouse models of I/R injury. Nitrite may serve as a therapeutic treatment for I/R disease, particularly in preventing organ dysfunction following surgery or transplantation.
A Umeå research team has made a breakthrough in understanding how obesity causes diabetes, fatty liver, and blood-fat disturbances. The study found that mice lacking a specific receptor, GPR40, are protected from these complications when fed a calorie-rich diet.
A new mouse model has shown reduced blood glucose levels and lower serum insulin, indicating improved glucose tolerance in the liver. The study found that Gab1 acts as a negative regulator on insulin signal strength in the liver, suggesting potential therapeutic targets for type 2 diabetes.
Researchers at Wake Forest University School of Medicine have found that the liver is the main source of high-density lipoprotein (HDL), or 'good' cholesterol. This discovery could lead to new treatments for raising HDL levels, particularly in individuals with less severe cholesterol disorders.
Researchers have discovered a new role for NKT cells in the liver, which crawl along vessel walls to detect foreign molecules and trigger an immune response. This finding offers a potential new approach to treating hepatitis by manipulating the NKT cell's behavior and reducing inflammation.
Scientists discover NKT cells primarily patrol liver blood vessels, showcasing agility and rapid movement. The study reveals surprises about NKT cell behavior, including their ability to survive without the CXCR6 gene.
The NASH Clinical Research Network is launching two trials to treat nonalcoholic steatohepatitis (NASH), a leading cause of cirrhosis in the US. The trials will test the efficacy of insulin-sensitizing agents and antioxidants, such as vitamin E, in slowing or reversing disease progression.
A systematic review found that Hepatitis C significantly impacts quality of life, affecting physical and social function, general health and vitality. Researchers established a minimally clinically important difference in vitality scale to monitor patient outcomes.
Research suggests statins can cause asymptomatic elevation of aminotransferases, especially at higher doses, but rare reports of significant liver injury exist; monitoring liver values is recommended for patients on statins, particularly those with known liver conditions.
Scientists have identified two populations of immune cells in the liver that can cause scarring and break it down. This discovery may lead to future treatments for liver damage and cirrhosis, a condition that affects more women in the UK than cervical cancer.
A study of liver transplant patients found that older donors, longer cold ischemia times, and urgent recipient status are significant risk factors for shortened graft survival. The results suggest a new model to predict post-transplant survival, potentially improving organ allocation decisions.
A study of 54 patients with ALD who underwent liver transplants found that those who resumed alcohol consumption had significantly lower 10-year survival rates compared to abstinent patients. Higher mortality rates among relapse group were attributed to increased risk of cancers and cardiovascular events.
A study of liver transplant patients with hepatitis C found that donor age does not impact long-term survival rates. Instead, maintenance azathioprine was associated with improved overall and 3-month survival rates, suggesting a complex relationship between immunosuppression and disease progression.
Researchers have developed a gene therapy that completely cures Crigler-Najjar syndrome, a liver disease, in rats using a specially designed adenovirus. The treatment has no long-term effect and poses no risk of cancer, making it a promising approach for treating other diseases with similar genetic deficiencies.
Research reveals that IL-6 activates a pathway in liver cells that triggers protection against hepatitis and immune-mediated liver damage. Two proteins, KC and SAA2, play a crucial role in this protective effect.
Researchers identify new therapeutic targets for immune-mediated liver diseases and explore the role of IL-6 in protecting liver cells. Osteopontin is also found to play a central role in amplifying rheumatoid arthritis, suggesting potential new treatments for this inflammatory condition.
Researchers discovered that sirtuin1 and PGC1-alpha proteins interact to trigger glucose production in the liver. Targeting this interaction could help control sugar production in people with diabetes, potentially leading to new treatment options.
Researchers have successfully replicated the hepatitis C virus (HCV) in a laboratory setting using a new in vitro model system. The system allows for the study of HCV therapeutics and the entire virus life cycle, including replication, assembly, and release from host cells.
A Pitt researcher has developed a decision-making model to help patients weigh the risks and benefits of accepting organ transplants. The model uses mathematical techniques to provide insight into patient physiology and quality of life, helping doctors make informed decisions.
The study found that EGCG protected fatty livers from cell damage after I/R injury, reducing necrosis and increasing viable tissue. It also reduced liver fat content by approximately 55 percent and increased hepatic energy stores.
Researchers found that adding serum sodium to the MELD score significantly increases its accuracy in predicting short-term mortality among liver transplant patients with advanced cirrhosis. The study showed that hyponatremia was a more accurate marker of poor outcome than serum creatinine.
Researchers found that chronic lymphocytic leukemia (CLL) cells are born at a fast rate but die, leading to a slow rise in cell count over time due to variable birth and death rates. This dynamic interplay between CLL cell division and cell death may enable physicians to predict disease progression.
Researchers found a biochemical switch, PGC-1beta, in liver cells that triggers the harmful effects of saturated and trans fats. The discovery offers hope for developing drug therapies to lower cholesterol levels and heart disease risk.
A study published in Liver Transplantation found that liver disease severity does not accurately predict quality of life, suggesting alternative methods should be considered for organ allocation. Patients with end-stage liver disease experience impaired quality of life, but this is not correlated with MELD scores.
A study of 742 patients with newly diagnosed chronic liver disease found that ethnicity significantly impacts NAFLD prevalence, particularly among Hispanic and Asian populations. The study highlights the need for culturally sensitive education and representation in future clinical studies to address disparities in diagnosis and treatment.
A new study reveals that liver disease can impair learning ability by disrupting the glutamate-nitric oxide-cGMP pathway in the brain. Sildenafil treatment restored learning ability in rats with portacaval shunts and those with hyperammonemia, suggesting a potential therapeutic approach for patients with hepatic encephalopathy.
Researchers have identified two types of immune cells in the liver that can cause scarring or repair it. Understanding these cells may lead to new treatments for cirrhosis, a major cause of liver failure.
Researchers found that transplanted bone marrow cells reduced liver fibrosis in mice treated with carbon tetrachloride. The treatment also improved survival rates and increased serum albumin levels, suggesting a new concept for treating liver fibrosis.
Researchers used 3D MDCT to evaluate patients before surgery and found that abnormal liver artery anatomy increases the risk of complications after a transplant. The study analyzed over 80 patients and found that those with variant anatomy were more likely to experience post-surgical complications.
A patient with a 20-year history of heavy drinking underwent liver transplantation in 1999 and experienced progressive recovery of strength in both legs. The authors suggest that peripheral neuropathy in patients with alcoholic cirrhosis is reversible and should not be a contraindication to liver transplantation.
A multicenter study found that early steroid withdrawal after liver transplantation increased acute rejection rates, but may decrease the risk of long-term cardiovascular disease and mortality. The study suggested that earlier withdrawal could lead to improved glucose tolerance and reduced metabolic complications.
T cells activated during IBD found in PSC livers, re-routed by aberrant attractant protein. Long-lived memory cells may explain delayed liver disease onset after IBD resolution.
Researchers at University of Toronto found evidence of lead contamination resulting from bismuth use in waterfowl samples. The study suggests that excessive bismuth exposure may be linked to blood, liver, kidney and neural problems.
Researchers found that treating mothers with IgG during pregnancy significantly reduced the severity of recurrent NH in newborns. The study showed that all 16 pregnancies progressed uneventfully and resulted in live babies with normal physical examination findings.
Researchers found elevated caspase levels in HCV patients with normal aminotransferase levels, associated with higher stages of liver fibrosis. The study suggests that measuring caspase-mediated CK-18 cleavage in serum may be a more sensitive method to detect liver fibrosis in chronic HCV infection.
Researchers found that combining liver transplantation and coronary artery bypass grafting is a safe approach for patients with severe coronary artery disease and end-stage liver disease. The procedure's success depends on careful multidisciplinary evaluation, coordination, and graft selection.
Researchers demonstrate that long-term maintenance therapy with peginterferon alfa-2b can prevent or delay the progression of hepatitis C, reducing the risk of liver damage by half. A new antiviral agent, NM283, also shows promising activity against genotype 1 HCV, offering hope for future therapies.
A study of nearly 400 African-American patients found that weight-based REBETOL dosing with PEG-INTRON improved viral clearance and reduced relapse rates compared to a flat dose. The treatment showed promise in improving outcomes for this patient population, which has historically had lower response rates to hepatitis C therapy.
A new study finds that combining Pegasys with ribavirin reduces hepatitis C viral levels more effectively than Peg-Intron, a promising development in treating the virus. The study's lead investigator hopes that the findings will inform the design of better drugs to combat the infection.
In a subgroup of high-risk patients, VYTORIN significantly reduced LDL cholesterol by 59% compared to Lipitor. This resulted in more patients achieving an LDL cholesterol goal of less than 100mg/dL with VYTORIN, and increased HDL cholesterol levels.
Researchers at Thomas Jefferson University found a significant decrease in liver rejection rates using a monoclonal antibody, basiliximab, in combination with tacrolimus and low-dose steroids. The one-year survival rate improved to 88%, with no complications reported.